GlassScriptPhysician profile
David Elkayam
NPI 1871589234
$39,432.90
in general payments reported to CMS, 2019-2025
34 companies · $14K in 2025
The $14K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,950 · 2020: $6,274 · 2021: $66.07 · 2022: $1,992 · 2023: $3,364 · 2024: $7,052 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $3,625 · Travel and Lodging: $284 · Education: $7.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,233.55 |
| Food and Beverage | $3,625.37 |
| Travel and Lodging | $283.59 |
| Education | $7.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Consortium of Independent Immunology Clinics, LLC | $18,600.00 | 2024-2025 | |
| Optinose US, INC. | $11,150.83 | 2019-2024 | |
| Grifols USA, LLC | $2,487.97 | 2023-2025 | Xembify, Gamunex-C |
| Pfizer INC. | $1,725.55 | 2022-2025 | |
| Alk-Abello, INC | $1,671.14 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Genzyme Corporation | $445.74 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $371.82 | 2019-2025 | Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $329.67 | 2022-2025 | Takhzyro, Cuvitru, Hyqvia |
| Genentech USA, INC. | $312.20 | 2023-2025 | Xolair |
| Amgen INC. | $262.93 | 2023-2025 | Tezspire, Actimmune |
| Novartis Pharmaceuticals Corporation | $230.80 | 2023-2025 | |
| Octapharma USA, INC. | $195.42 | 2019-2024 | Octagam Immune Globulin (Human) |
| Csl Behring | $192.88 | 2019-2025 | Hizentra, Andembry |
| Pharming Healthcare, INC. | $187.62 | 2022-2025 | Ruconest |
| Blueprint Medicines Corporation | $175.06 | 2023-2025 | Ayvakit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $172.25 | 2024-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $166.47 | 2023-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $147.36 | 2022-2025 | Orladeyo |
| Merck Sharp & Dohme LLC | $139.55 | 2022-2023 | |
| Circassia INC. | $114.97 | 2019 | |
| Abbvie INC. | $90.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $66.01 | 2019-2021 | |
| Adma Biomanufacturing LLC | $53.55 | 2024-2025 | |
| Kaleo, INC. | $37.74 | 2022-2023 | Auvi-Q |
| Tersera Therapeutics LLC | $35.97 | 2025 | Quzyttir |
| Ars Pharmaceuticals Operations, INC. | $27.70 | 2025 | Neffy |
| Cycle Pharmaceuticals INC | $21.73 | 2025 | Sajazir |
| Ionis Pharmaceuticals, INC. | $19.87 | 2025 | Dawnzera |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Elkayam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.